Yiheng Capital Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-191,076
| Closed | -$9.07M | – | 25 |
|
|
2025
Q3 | $9.07M | Sell |
191,076
-108,715
| -36% | -$5.26M | 1.34% | 14 |
|
|
2025
Q2 | $16M | Sell |
299,791
-60,000
| -17% | -$2.73M | 1.44% | 11 |
|
|
2025
Q1 | $14.6M | Sell |
359,791
-306,354
| -46% | -$13M | 1.35% | 11 |
|
|
2024
Q4 | $18.5M | Sell |
666,145
-92,624
| -12% | -$2.81M | 0.71% | 12 |
|
|
2024
Q3 | $21.8M | Sell |
758,769
-675,410
| -47% | -$17.6M | 1.12% | 10 |
|
|
2024
Q2 | $33.6M | Hold |
1,434,179
| – | – | 2.71% | 11 |
|
|
2024
Q1 | $36.2M | Sell |
1,434,179
-489,495
| -25% | -$11.8M | 2.01% | 11 |
|
|
2023
Q4 | $44.9M | Buy |
1,923,674
+702,000
| +57% | +$13.8M | 2.59% | 11 |
|
|
2023
Q3 | $61.8M | Buy |
1,221,674
+20,083
| +2% | +$935K | 3.15% | 10 |
|
|
2023
Q2 | $56.1M | Buy |
1,201,591
+75,800
| +7% | +$3.47M | 3.03% | 11 |
|
|
2023
Q1 | $43.1M | Sell |
1,125,791
-343,114
| -23% | -$15.3M | 1.7% | 15 |
|
|
2022
Q4 | $80.5M | Sell |
1,468,905
-630,241
| -30% | -$27M | 3.56% | 8 |
|
|
2022
Q3 | $71.5M | Buy |
2,099,146
+216,448
| +11% | +$3.31M | 4.41% | 8 |
|
|
2022
Q2 | $17.8M | Buy |
1,882,698
+329,708
| +21% | +$3.44M | 1.02% | 22 |
|
|
2022
Q1 | $22M | Buy |
1,552,990
+1,900
| +0.1% | +$33.3K | 1.01% | 22 |
|
|
2021
Q4 | $32.8M | Buy |
1,551,090
+29,900
| +2% | +$663K | 1.67% | 16 |
|
|
2021
Q3 | $34M | Buy |
1,521,190
+22,252
| +1% | +$504K | 1.67% | 18 |
|
|
2021
Q2 | $37.2M | Buy |
1,498,938
+1,230,656
| +459% | +$34.6M | 1.5% | 15 |
|
|
2021
Q1 | $7.78M | Buy |
+268,282
| New | +$8.12M | 0.35% | 20 |
|
Other funds holding AKRO
Yiheng Capital Management's AKRO Position: Q4 2025 in Review
Yiheng Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 191,076 shares — an estimated $9.07M sold.
Yiheng Capital Management first reported a position in AKRO in Q1 2021 and held it in 19 quarters. The position peaked at $80.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Yiheng Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Yiheng Capital Management sold 191,076 Akero Therapeutics shares in Q4 2025, an estimated $9.07M.
- Yiheng Capital Management first reported a position in Akero Therapeutics in Q1 2021 and held it in 19 quarters.
- Yiheng Capital Management's Akero Therapeutics position peaked at $80.5M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Yiheng Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.